Simon Patterson Joins GoodRx Board of Directors
May 30 2024 - 3:05PM
Business Wire
Former Dell Technologies and Skype Board member
brings decades of tech, strategy and management experience to
GoodRx
GoodRx (Nasdaq: GDRX), the leading destination for prescription
savings in the U.S., today announced the election of Simon
Patterson to its Board of Directors. Currently leading EMEA
operations for the technology investment firm Silver Lake, Mr.
Patterson brings to GoodRx decades of technology, strategy and
management experience. Mr. Patterson also serves on the boards of
IVC Evidensia, New Zealand Rugby Commercial, RAC, and ZPG, and
previously served on the boards of Cegid, Dell Technologies,
FlixBus, Gerson Lehrman Group, Intelsat, MultiPlan and Skype.
“We believe Mr. Patterson’s significant expertise in finance and
management, formed by his extensive experience operating, advising
and investing in high-growth technology companies, will be a strong
asset to GoodRx,” said Trevor Bezdek, GoodRx co-founder and
Chairman of the Board. “We look forward to benefiting from his
business acumen as we scale our business to make prescription
medications more accessible and affordable for all Americans.”
Mr. Patterson has also joined the Board’s Nominating and
Corporate Governance Committee.
About GoodRx
GoodRx is the leading destination for prescription savings in
the U.S. We offer consumers free access to transparent and lower
prices for generic and brand medications, as well as comprehensive
healthcare research and information. We also equip healthcare
professionals with efficient ways to find and prescribe affordable
medications. Since 2011, GoodRx has helped consumers save nearly
$75 billion and is one of the most downloaded medical apps over the
past decade.
GoodRx periodically posts information that may be important to
investors on its investor relations website at
https://investors.goodrx.com. We intend to use our website as a
means of disclosing material nonpublic information and for
complying with our disclosure obligations under Regulation FD.
Accordingly, investors and potential investors are encouraged to
consult GoodRx’s website regularly for important information, in
addition to following GoodRx’s press releases, filings with the
Securities and Exchange Commission (the “SEC”) and public
conference calls and webcasts. The information contained on, or
that may be accessed through, GoodRx’s website is not incorporated
by reference into, and is not a part of, this press release.
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding the scaling of our business, benefits to consumers from
our offerings and anticipated contributions from Simon Patterson in
his directorship. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to,
risks relating to our ability to attract and retain talent and the
important factors discussed under the caption “Risk Factors” in
GoodRx’s Annual Report on Form 10-K for the year ended December 31,
2023, and our other filings with the SEC. These factors could cause
actual results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of
the date of this press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim
any obligation to do so, even if subsequent events cause our views
to change.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240530591769/en/
Investor Contact ir@goodrx.com Media Contact
press@goodrx.com
GoodRx (NASDAQ:GDRX)
Historical Stock Chart
From May 2024 to Jun 2024
GoodRx (NASDAQ:GDRX)
Historical Stock Chart
From Jun 2023 to Jun 2024